This is a non-significant risk, multi-center, randomized, active-controlled study to compare the effectiveness of two digital therapies in the management of fibromyalgia over 12 weeks. The primary endpoint is mean change from baseline to Week 12 in the weekly revised Fibromyalgia Impact Questionnaire (FIQ-R) total score.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
67
Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.
Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.
Excell Research, Inc.
Oceanside, California, United States
Superior Research LLC
Sacramento, California, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Upstate Clinical Research Associates LLC
Williamsville, New York, United States
Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score
FIQ-R total score ranges between 0-100 with a reduction in score indicating reduced fibromyalgia severity.
Time frame: Baseline to Week 12
Key Secondary Endpoint of This Clinical Trial - Rate of Patient's Global Impression of Change (PGIC) Responders at Week 12 - Any Improvement
PGIC scores included are: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse
Time frame: Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Cincinnati Physicians Company, LLC
Cincinnati, Ohio, United States
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio, United States
Lehigh Center for Clinical Research
Allentown, Pennsylvania, United States